Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012&amp;ndash;2013

Hollingworth, Kate; Davis, Kourtney J.; Landis, Sarah H.; Muellerova, Hana; Mannino, David M.; Menezes, Ana Maria Baptista; Han, MeiLan K.; Ichinose, Masakazu; Айсанов, З. Р.; Oh, Yeon‐Mok; Molen, Thys van der

doi:10.2147/copd.s61854

Cited by 103 publications

(92 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In each of the age cohorts, more than half of patients had a CAT score ≥10, indicating a high impact of COPD on patients’ HRQoL. This was in line with a population-based survey in Japan that revealed a mean CAT score of 16 points – similar to that observed in this study 35. Earlier studies have shown a strong correlation with the CAT questionnaire with severity of airflow obstruction, dyspnea and comorbidities in Japanese patients 13,36.…”

Section: Discussionsupporting

confidence: 90%

COPD uncovered: a cross-sectional study to assess the socioeconomic burden of COPD in Japan

Igarashi¹,

Fukuchi²,

Hirata³

et al. 2018

COPD

Self Cite

View full text Add to dashboard Cite

BackgroundCOPD remains a major health problem in Japan. Patients with COPD experience a reduced quality of life (QoL) and have a higher chance of work impairment and productivity loss. However, there is a lack of data on the impact of COPD in terms of QoL and work activity impairment in Japan. This study assessed the socioeconomic burden of COPD in Japan and the impact it may have on the working age population.Patients and methodsThis was a 2-year retrospective chart review in COPD patients aged ≥40 years, with at least one health care visit to clinic or hospital in the previous 12 months. Patients were required to have available medical charts for at least the previous 24 months. Symptoms were assessed using COPD assessment test score; EuroQoL Group 5 Dimension (EQ-5D-5L) and work productivity and activity impairment general health questionnaires were used to evaluate health-related QoL and work productivity, and health care resource utilization data were obtained from clinical charts.ResultsIn total, 71 patients aged <65 years, and 151 patients aged ≥65 years were included; the majority of patients had moderate or severe airflow limitation. Exacerbations (moderate or severe) were reported by ~35% of patients in both age groups; 52.1% and 62.9% of patients in the <65-year and ≥65-year age groups had COPD assessment test scores ≥10. EQ-5D-5L index scores in the <65-year and ≥65-year age groups were 0.79 and 0.77, respectively. Work productivity and activity impairment scores were higher in <65-year age group. Annual costs of health care resource use per patient in the <65-year and ≥65-year age groups were ¥438,975 (US$4,389) and ¥467,871 (US$4,678), respectively. Costs due to productivity loss were estimated to be ¥5,287,024 (US$52,870) in the <65-year age group and ¥3,018,974 (US$30,187) in the ≥65-year age group.ConclusionCOPD represents a significant socioeconomic burden in Japan. Patients with COPD report significant use of health care resources. Higher impact on work impairment and productivity loss was observed frequently in the working age population.

show abstract

Section: Discussionsupporting

confidence: 90%

COPD uncovered: a cross-sectional study to assess the socioeconomic burden of COPD in Japan

Igarashi¹,

Fukuchi²,

Hirata³

et al. 2018

COPD

Self Cite

View full text Add to dashboard Cite

show abstract

“…The phenotypic distribution involving both airway and systemic inflammation, in addition to airway obstruction, is similar to that previously described in Western studies 25. A global survey24 also confirmed findings that COPD causes a high societal and personal burden, as demonstrated by high levels of symptoms, poor health status, and high frequency of severe exacerbations of COPD. Given the high prevalence of smoking in Japan, coupled with its aging population, the prevalence of the disease in the country is likely to increase over the next 20–40 years, further increasing the burden of COPD.…”

Section: Epidemiology and Treatment Of Copd In Japansupporting

confidence: 84%

“…A global survey of patients with physician-diagnosed COPD or emphysema or with physician-diagnosed or symptom-based chronic bronchitis reported a prevalence of COPD of 7% in a Japanese population aged 40 years or older 24. The phenotypic distribution involving both airway and systemic inflammation, in addition to airway obstruction, is similar to that previously described in Western studies 25.…”

Section: Epidemiology and Treatment Of Copd In Japansupporting

confidence: 66%

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes

Hizawa¹

2015

COPD

View full text Add to dashboard Cite

In the combined use of bronchodilators of different classes, ie, long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), bronchodilation is obtained both directly, through LABA-mediated stimulation of β2-adrenergic receptors, and indirectly, through LAMA-mediated inhibition of acetylcholine action at muscarinic receptors. The clinical trial data for LABAs/LAMAs in the treatment of chronic obstructive pulmonary disease (COPD) continue to be promising, and these combinations will provide the convenience of delivering the two major bronchodilator classes, recommended as first-line maintenance options in COPD treatment guidelines. COPD is a complex condition that has pulmonary and extrapulmonary manifestations. These clinical manifestations are highly variable, and several are associated with different responses to currently available therapies. The concept of a COPD phenotype is rapidly evolving from one focusing on the clinical characteristics to one linking the underlying biology to the phenotype of the disease. Identification of the peculiarities of the different COPD phenotypes will permit us to implement a more personalized treatment in which the patient’s characteristics, together with his or her genotype, will be key to choosing the best treatment option. At present in Japan, fixed combinations of inhaled corticosteroids (ICSs) and LABAs are frequently prescribed in the earlier stages of COPD. However, ICSs increase the risk of pneumonia. Notably, 10%–30% of patients with COPD with or without a history of asthma have persistent circulating and airway eosinophilia associated with an increased risk of exacerbations and sensitivity to steroids. Thus, sputum or blood eosinophil counts might identify a subpopulation in which ICSs could have potentially deleterious effects as well as a subpopulation that benefits from ICSs. In this review, I propose one plausible approach to position ICSs and LABAs/LAMAs in clinical practice, based on both the extent of airflow obstruction and the presence of an asthma component or airway eosinophilic inflammation. This approach is a tentative move toward personalized treatment for COPD patients, and with progress in knowledge and developments in physiology, lung imaging, medical biology, and genetics, identification of COPD phenotypes that provide prognostic and therapeutic information that can affect clinically meaningful outcomes is an urgent medical need.

show abstract

“…At 12 weeks, 24 weeks, 36 weeks, and 52 weeks, a follow-up interview was conducted by telephone, gathering information on productivity losses, health care utilization, and exacerbations of respiratory symptoms. Follow-up by telephone was considered satisfactory as no biological measurements were needed, the interval between interviews was short, and telephone coverage was reliable in the area 32,33. Information on comorbidities was gathered by asking for conditions listed in the Charlson Comorbidity Index 34…”

Section: Methodsmentioning

confidence: 99%

Incidence of utilization- and symptom-defined COPD exacerbations in hospital- and population-recruited patients

Erdal

Johannessen

Eagan

et al. 2016

COPD

View full text Add to dashboard Cite

ObjectivesThe objectives of this study were to estimate the impact of recruitment source and outcome definition on the incidence of acute exacerbations of COPD (AECOPD) and explore possible predictors of AECOPD.Patients and methodsDuring a 1-year follow-up, we performed a baseline visit and four telephone interviews of 81 COPD patients and 132 controls recruited from a population-based survey and 205 hospital-recruited COPD patients. Both a definition based on health care utilization and a symptom-based definition of AECOPD were applied. For multivariate analyses, we chose a negative binomial regression model.ResultsCOPD patients from the population- and hospital-based samples experienced on average 0.4 utilization-defined and 2.9 symptom-defined versus 1.0 and 5.9 annual exacerbations, respectively. The incidence rate ratios for utilization-defined AECOPD were 2.45 (95% CI 1.22–4.95), 3.43 (95% CI 1.59–7.38), and 5.67 (95% CI 2.58–12.48) with Global Initiative on Obstructive Lung Disease spirometric stages II, III, and IV, respectively. The corresponding incidence rate ratios for the symptom-based definition were 3.08 (95% CI 1.96–4.84), 3.45 (95% CI 1.92–6.18), and 4.00 (95% CI 2.09–7.66). Maintenance therapy (regular long-acting muscarinic antagonists, long-acting beta-2 agonists, inhaled corticosteroids, or theophylline) also increased the risk of AECOPD with both exacerbation definitions (incidence rate ratios 1.65 and 1.73, respectively). The risk of AECOPD was 59%–78% higher in the hospital sample than in the population sample.ConclusionIf externally valid conclusions are to be made regarding incidence and predictors of AECOPD, studies should be based on general population samples or adjustments should be made on account of a likely higher incidence in other samples. Likewise, the effect of different AECOPD definitions should be taken into consideration.

show abstract

Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013

Cited by 103 publications

References 42 publications

COPD uncovered: a cross-sectional study to assess the socioeconomic burden of COPD in Japan

COPD uncovered: a cross-sectional study to assess the socioeconomic burden of COPD in Japan

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes

Incidence of utilization- and symptom-defined COPD exacerbations in hospital- and population-recruited patients

Contact Info

Product

Resources

About